Company Filing History:
Years Active: 2017
Title: Kathrin Stirnemann: Pioneering Advances in Immune Modulation
Introduction
Kathrin Stirnemann, based in Zurich, Switzerland, is an accomplished inventor in the field of immunology. Her work focuses on the modulation of immune responses, particularly through innovative approaches involving NKT (natural killer T) cells. With one patent to her name, she has made significant strides in understanding and manipulating immune mechanisms.
Latest Patents
Kathrin Stirnemann holds a patent titled "Modulation of NKT cell activity with antigen-loaded CD1d molecules." This invention encompasses methods for modulating immune responses in animals by administering a composition containing soluble CD1d complexes. These complexes consist of a soluble CD1d polypeptide, a β2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound within the CD1d antigen binding groove. The innovation allows for multiple administrations without triggering CD1d-restricted NKT cell anergy, which could pave the way for improved therapeutic strategies in immunology.
Career Highlights
Stirnemann works with Vaccinex, Inc., where her contributions have been instrumental in advancing research related to immune modulation. Her expertise in the field has allowed her to focus on developing practical applications for her innovative ideas, cementing her status as a notable inventor in the sector.
Collaborations
Throughout her career, Kathrin has collaborated with notable colleagues, including Alena Donda and Jean-Pierre Mach. These partnerships have enriched her research and combined expertise in the field of immunology, fostering a collaborative environment for innovation and discovery.
Conclusion
Kathrin Stirnemann represents a significant figure in the world of immunological research and innovation. Her patented work on NKT cell activity reflects her commitment to advancing medical science and enhancing immune response therapies. With her ongoing collaborations and innovative contributions, she continues to make an impact in the field, promising a brighter future for immunological advancements.